The AI generated statement is erroneous once again. Experts do not agree that Tafadamis (Vyndamax)and Attruby offer same benefits or that neither is better than the other.
August 14
Both Vyndamax (tafamidis) and Attruby (acoramidis) are oral medications approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM). They work in a similar way — both are TTR stabilizers, meaning they help keep the transthyretin protein from breaking apart and forming harmful amyloid deposits in the heart.
Here's a Show Full Answer
Both Vyndamax (tafamidis) and Attruby (acoramidis) are oral medications approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM). They work in a similar way — both are TTR stabilizers, meaning they help keep the transthyretin protein from breaking apart and forming harmful amyloid deposits in the heart.
Here's a quick side-by-side comparison:
- Vyndamax (tafamidis): FDA-approved in 2019, taken orally once daily
- Attruby (acoramidis): FDA-approved in 2024, taken orally twice daily
Both are approved for wild-type and hereditary ATTR-CM. A recent phase 3 study showed that acoramidis (Attruby) reduced the risk of cardiovascular death or repeat hospitalizations by 49% compared to placebo, which is a strong result. Tafamidis also has solid long-term data, including a study showing 93% of people with hATTR were still alive at 10 years.
Experts stress that neither drug is definitively better than the other — they're both considered excellent options. As one specialist put it, "the only wrong option is to be on none of them."
The best choice really comes down to individual factors like your specific type of ATTR-CM, insurance coverage, and what works best for your lifestyle. It's worth having a detailed conversation with your amyloidosis specialist to figure out which one fits your situation best.
August 13
I’m on both for ATTR- wt.
August 18
Join
Your Privacy Choices
